STRO
Sutro Biopharma, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
20.72
▼ 0.44 (2.08%)
MARKET · —
Price
Open
20.59
Prev close
21.16
Day high
21.82
Day low
20.86
Volume
193.62K
Market cap
$348.87M
P/E (TTM)
—
52W range
7.15 – 43.85
Trailing performance
Returnvs SPY
1W
+2.73%
+4.1%
1M
-10.85%
-14.6%
3M
-31.29%
-34.4%
6M
+14.22%
+3.2%
YTD
+81.85%
+69.6%
1Y
+144.65%
+124.7%
3Y
-47.53%
-121.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$348.87M
Enterprise value$195.30M
Revenue (TTM)$45.70M
Gross profit$-99.04M
EBITDA$-125.80M
Net income$-180.64M
EPS (TTM)$-17.37
Free cash flow$-100.76M
Total cash$164.35M
Total debt$10.78M
Book value / share$-4.04
Shares outstanding16.58M
Float10.77M
Short % of float10.56%
Dividend yield—
Beta (5Y)1.52
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.39
PEG ratio—
Price / sales—
Price / book—
EV / revenue4.27
EV / EBITDA-1.55
Gross margin-216.71%
Operating margin-301.73%
Profit margin0.00%
Return on equity—
Return on assets-36.08%
Debt / equity—
Current ratio3.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $102.48M | $62.04M | $153.73M | $67.77M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$191.09M | -$227.46M | -$106.79M | -$119.20M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$191.09M | -$227.46M | -$106.79M | -$119.20M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.27 | -2.31 | -1.9% |
| Mar 2026 | -3.22 | -2.94 | +8.6% |
| Dec 2025 | -4.43 | -4.88 | -10.2% |
| Jun 2025 | -3.82 | -1.40 | +63.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -2.27 | 2 | $11.04M | -82.7% |
| Next quarter | -1.92 | 2 | $13.59M | +16.7% |
| Current year | -7.77 | 3 | $51.55M | -49.7% |
| Next year | -6.72 | 3 | $31.59M | -38.7% |
Analyst targets & ownership
Mean target$47.23
High target$61.00
Low target$10.00
Implied upside127.95%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy3 / 10
Hold0
Sell / Strong sell0 / 1
Held by insiders2.26%
Held by institutions98.57%
Institutions holding139
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
374.40K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 2, 26 | CHOW GREGORY KWOK LEE Chief Financial Officer |
— | 2.50K | — | Direct |
| Mar 4, 26 | PAULING DAVID J.D. General Counsel |
— | 675 | — | Direct |
| Mar 4, 26 | CHUNG JANE Chief Executive Officer |
— | 788 | — | Direct |
| Mar 2, 26 | GERBER HANS-PETER PH.D. Officer |
— | 3.97K | — | Direct |
| Mar 2, 26 | PAULING DAVID J.D. General Counsel |
— | 3.70K | — | Direct |
| Mar 2, 26 | CHUNG JANE Chief Executive Officer |
— | 10.94K | — | Direct |
| Dec 12, 25 | CHUNG JANE Chief Executive Officer |
— | 2.50K | — | Direct |
| Oct 15, 25 | MATSUI CONNIE L Director |
BUY | 50.00K | $39.95K | Direct |
| Oct 15, 25 | CHOW GREGORY KWOK LEE Chief Financial Officer |
BUY | 19.75K | $16.00K | Direct |
| Oct 15, 25 | CHUNG JANE Chief Executive Officer |
BUY | 12.50K | $10.01K | Direct |
| Oct 15, 25 | GERBER HANS-PETER PH.D. Officer |
BUY | 17.00K | $13.61K | Direct |
| Oct 15, 25 | PAULING DAVID J.D. General Counsel |
BUY | 12.50K | $9.99K | Direct |
| Sep 18, 25 | GERBER HANS-PETER PH.D. Officer |
— | 37.50K | — | Direct |
| Aug 8, 25 | CHUNG JANE Chief Executive Officer |
— | 18.75K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALBINI EDWARD C |
Chief Financial Officer | 160.81K | Conversion of Exercise of derivative security |
BORGMAN ANNE ELIZABETH |
Officer | 97.45K | Conversion of Exercise of derivative security |
CHUNG JANE |
Chief Executive Officer | 21.29K | Conversion of Exercise of derivative security |
FITZPATRICK LINDA A. |
Officer | 130.13K | Conversion of Exercise of derivative security |
GERBER HANS-PETER PH.D. |
Officer | 9.52K | Conversion of Exercise of derivative security |
LEYMAN BARBARA |
Officer | 16.06K | Conversion of Exercise of derivative security |
MATSUI CONNIE L |
Director | 50.00K | Purchase |
NEWELL WILLIAM J |
Chief Executive Officer | 409.06K | Conversion of Exercise of derivative security |
PAULING DAVID J.D. |
General Counsel | 9.75K | Conversion of Exercise of derivative security |
SRINIVASAN VENKATESH |
Officer | 53.69K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
22.21
-6.70% from price
SMA 20
23.38
-10.00% from price
SMA 50
26.28
-19.95% from price
SMA 100
28.83
-28.14% from price
SMA 200
21.66
-2.88% from price
EMA 12
22.36
-7.32% from price
EMA 26
23.71
-12.62% from price
EMA 50
25.31
-18.13% from price
RSI (14)
37.3
Neutral
MACD (12,26,9)
-1.36
Hist -0.11
ATR (14)
2.03
9.67% of price
Realised vol 30D
75.1%
Annualised
Bollinger upper
26.81
20, 2σ
Bollinger lower
19.94
20, 2σ
50 / 200 cross
Golden
26.28 vs 21.66
Trend bias
Below 200
-2.88%
Risk profile
Beta vs SPY
1.18
More volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
75.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-49.9%
Peak to trough
Max drawdown 5Y
-97.8%
Peak to trough
ATR 14
2.03
9.67% of price
Beta (reported)
1.52
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
3.00
Put-heavy session
Put / call open interest
49.00
Positioning, not flow
Max pain
22.50
+6.9% from spot
ATM implied vol
164.8%
Nearest strike to spot
Skew (10% OTM)
-57.0%
Calls bid over puts
Call volume
1
Contracts, this expiry
Put volume
3
Contracts, this expiry
Heaviest call OI
12.50
1 contracts
Heaviest put OI
20.00
27 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
STRO Stock Plummets 15% — What Drove The Selloff?
Stocktwits · 10d ago
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
GlobeNewswire · 10d ago
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 11d ago
SpaceX upgraded, Trade Desk downgraded: Wall Street's top analyst calls
The Fly · 15d ago
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 17d ago
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Motley Fool · 83d ago
Barclays initiates oncology-focused biotechs with positive outlook
Investing.com · 86d ago
Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target
MT Newswires · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.